RT Journal Article
SR Electronic
T1 Interstitial Fibrosis and Arrhythmic Mitral Valve Prolapse: Unravelling Sex-Based Differences
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.01.12.24301217
DO 10.1101/2024.01.12.24301217
A1 Tastet, Lionel
A1 Dixit, Shalini
A1 Nguyen, Thuy
A1 Lim, Lisa J.
A1 Al-Akchar, Mohammad
A1 Bibby, Dwight
A1 Arya, Farzin
A1 Cristin, Luca
A1 Anwar, Shafkat
A1 Higuchi, Satoshi
A1 Hsia, Henry
A1 Lee, Yoo Jin
A1 Delling, Francesca N.
YR 2024
UL http://medrxiv.org/content/early/2024/01/13/2024.01.12.24301217.abstract
AB Background Interstitial fibrosis as quantified by cardiac magnetic resonance (CMR) has been demonstrated in arrhythmic mitral valve prolapse (MVP), a condition with known female predominance. However, prior studies included only MVP cases with significant mitral regurgitation (MR) or mitral annular disjunction (MAD). We sought to evaluate the association between interstitial fibrosis and complex ventricular ectopy (ComVE) in MVPs unselected for MAD or severe MR, and to investigate the contribution of sex to this association.Methods We performed contrast CMR in consecutive individuals with MVP between 2020 and 2022. Extracellular volume fraction (ECV%), a surrogate marker for interstitial fibrosis, was quantified using T1 mapping. Replacement fibrosis was assessed using late gadolinium enhancement (LGE). ComVE, defined as frequent premature ventricular contractions and/or non-sustained/sustained ventricular tachycardia (VT), was detected using ambulatory ECG monitoring.Results We identified 59 MVP cases without severe MR (49% women, 80% with mild or less MR) and available ECV% measurement. Among these, 23 (39%) had ComVE, including a case of aborted ventricular fibrillation (VF) and one with sudden arrhythmic death, both females. Global ECV% was significantly greater in ComVE versus non-ComVE (31%[27-33] vs 27%[23-30], p=0.002). In MVP-ComVE, higher segmental ECV% was not limited to the inferolateral/inferior LV wall, but was also demonstrated in atypical segments including the anterior/anterolateral wall (p<0.05). The association between ComVE and ECV% was driven by female sex (32%[30-33] vs 28%[26-30], p=0.003 in females; 31%[25-33] vs 26%[23-30], p=0.22 in males). ECV% remained independently associated with an increased risk of ComVE, including VT/VF, after adjustment for cardiovascular risk factors, MAD, and LGE (p<0.01).Conclusion In MVP without significant MR, interstitial fibrosis by CMR is associated with an increased risk of ComVE, suggesting a primary myopathic process. The stronger association between interstitial fibrosis and ComVE in females may explain why severe arrhythmic complications are more prevalent among women.GRAPHICAL ABSTRACT: Expansion of Interstitial Myocardial Fibrosis in Mitral Valve Prolapse with Complex Ventricular Ectopy. Illustrative MVP case with ComVE and greater interstitial fibrosis as demonstrated by T1 mapping on CMR (Top). The violin plot shows significantly greater ECV% in MVPs with ComVE compared to non-ComVE (Top). The association between greater interstitial fibrosis (i.e. ECV%) and ComVE was stronger in women than men (Bottom). MR = mitral regurgitationCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Institute of Health NHLBI R01HL153447.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee of UCSF approved the study and participants gave informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.MVPmitral valve prolapseMRmitral regurgitationSCDsudden cardiac deathLVleft ventricular/ventricleComVEcomplex ventricular ectopyLGElate gadolinium enhancementCMRcardiac magnetic resonanceECVextracellular volume fraction